Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of the PETAL trial is to determine whether patients with aggressive non-Hodgkin's lymphomas with a persistently positive PET scan after two cycles of chemotherapy benefit from a change of the treatment protocol.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Essen
• Collaborator: Deutsche Krebshilfe e.V., Bonn (Germany)
• Treatments: Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine

Criteria

Inclusion Criteria:

• Aggressive B-cell or T-cell non-Hodgkin's lymphoma

• Pathological pre-treatment PET scan

• Performance status ECOG 0-3

• Age 18 - 80 years

• Ability to understand the purpose of the study and act accordingly

• Willingness to use adequate contraception

• Informed consent

Exclusion Criteria:

• Burkitt's lymphoma

• Primary central nervous system lymphoma

• Previous chemo- and/or radiotherapy

• Other cancer within preceding 5 years

• HIV infection, active viral hepatitis or other uncontrolled infection

• Other medical conditions precluding administration of planned therapy

• Pregnancy or lactation